We’re looking for a Principal Product Designer to join our Design team! This is an exciting opportunity to create highly imaginative, intuitive experiences that empower individuals to gain insight into their genetic information. Come join our Gene Pool! https://lnkd.in/gNGz435v
About us
23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was named as one of the San Francisco Chronicle's Top Workplaces and one of Comparably's Best Places to Work in 2022. CEO, Anne Wojcicki was also named one of Glassdoor’s top CEOs in 2019 and one of Comparably’s "Best CEOs for Women" in 2021 and 2022. More information is available at www.23andMe.com.
- Website
-
https://www.23andme.com
External link for 23andMe
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Sunnyvale, California
- Type
- Public Company
- Specialties
- genetic research, consumer genetics, direct-to-consumer genetic testing, telehealth, healthcare, wellness, therapeutics, and drug discovery
Locations
-
Primary
223 N Mathilda Ave
Sunnyvale, California 94086, US
-
349 Oyster Point Blvd
South San Francisco, CA 94080, US
Employees at 23andMe
Updates
-
On September 14 and 15 our 23andMe Therapeutics team will present new data on our two clinical immuno-oncology programs, 23ME-00610 and 23ME-01473, at the ESMO Congress 2024 in Barcelona. We’ll publish the posters on our Therapeutics and IR sites, so watch this space - and if you’re in the neighborhood, feel free to swing by! https://23and.me/3MtWFXN
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024 | 23andMe, Inc.
investors.23andme.com
-
23andMe inches closer to cancer immunotherapy, guided by its genetic database. Dr. Jennifer Low, head of 23andMe’s therapeutics division, talks about the development of oncology checkpoint inhibitors that target a unique pathway. https://lnkd.in/g5Efvfhk
23andMe inches closer to cancer immunotherapy, guided by its genetic database
pharmamore.us
-
Yesterday we announced the launch of a new large-scale study to identify genetic and non-genetic associations with the weight loss variation and side effects experienced by people that take GLP-1 medications. We are hopeful that by exploring this field further, we can leverage the data uncovered to influence future personalized weight loss treatment options for varied individuals. For more information on the study, please visit: https://23and.me/4ciJ4gj
23andMe Launches Genetic Study of GLP-1s
blog.23andme.com
-
The National Association of Black Journalists (NABJ) and its members play a crucial role in informing and empowering communities through their reporting. We were honored to be a sponsor of last week's #NABJConvention to engage with these journalists in conversations around health and science and wellness. #NABJ2024
-
-
Attending the National Medical Association Annual Convention and Scientific Assembly in NYC this week? Visit us at booth #209 to learn more about how we’re helping people identify their genetic risks and take action. Plus, hear from our collaborator AfroPink,Inc about the ways we partner with community-based advocacy organizations to promote genetics-informed screening and prevention!
-
-
Have you heard the news? The award-winning musical Our Little Secret - a completely true story of Noam Tomaschoff's discovery that he wasn't an only child and how he learned through a 23andMe test that he had more than 35 siblings globally - is now showing at the biggest arts festival in the world, Edinburgh Fringe! It's running nightly at 5:30 PM at the Gilded Balloon Patter Hoose - Doonstairs, make sure to stop by if you're in town! https://lnkd.in/gfWWkPma
-
-
Last week, we joined 20 advocacy organizations to launch the Lung Cancer Genetics Study. With this study, we hope to learn more about the genetics behind the disease to transform our understanding of risk and treatment. Learn more here: https://23and.me/4dnvw47
-
-
Today we’re announcing a new study to advance research on lung cancer. While lung cancer research and targeted therapies have provided hope and progress for many, this study aims to learn more about the genetics behind the disease and its causes. Learn more here: https://23and.me/3zVjzEm
-
-
Powerful New York Magazine article on genetic testing for Alzheimer’s disease risk. We celebrate giving access to those who want to know their genetic risk. Genetic testing is a choice we believe gives people agency over their health and facilitates personalized prevention as early as possible. #prevention #genetics #alzheimers https://lnkd.in/gbzDyHs6
Ten People on Finding Out They Have the Alzheimer’s Gene
nymag.com